University System of Maryland

University of Pittsburgh

Eric J Sundberg

Steven Fletcher

Nicolas Paul Sluis-Cremer

Yohei Doi

Erik H Klontz

Adam Daniel Tomich

Beatriz Trastoy Bello

Compounds, pharmaceutical compositions, and methods for reversing fosfomycin resistance are disclosed. Embodiments of the disclosed compounds inhibit fosfomycin-inhibiting enzymes. Some embodiments of the compounds are FosA inhibitors. The disclosed pharmaceutical compositions include (i) fosfomycin or a pharmaceutically acceptable salt thereof and (ii) a compound, or a pharmaceutically acceptable salt thereof, which inhibits a fosfomycin-inhibiting enzyme. A method of inhibiting growth of a fosfomycin-resistant bacterium includes contacting the bacterium with (i) fosfomycin or a pharmaceutically acceptable salt thereof and (ii) an effective amount of a disclosed compound or a pharmaceutically acceptable salt thereof.

Reversal of fosfomycin resistance

Means for improving the effector functions of current immunotherapeutic antibodies through targeted hyper-glycosylation of the antibody Fc region are disclosed, as well as antibody variants having hyper-glycosylated Fc regions. Fc receptor-mediated effector functions have been shown to be a critical contributor to the efficacies of numerous therapeutic antibodies currently in clinical use. Targeted hyper-glycosylation of antibodies has the potential to significantly improve current immunotherapies for cancer.

Hyper-glycosylated antibodies with selective Fc receptor binding

Growing community of inventors

Baltimore, MD, United States of America

Eric J Sundberg